Clinical Trial Update: A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase II single-arm study of Iparomlimab and Tuvonralimab (QL1706) in combination with lenvatinib and transarterial chemoembolization for advanced hepatocellula…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• Tuvonralimab (QL1706)
• iparomlimab

Snippet

Sponsor: The Second Affiliated Hospital of Shandong First Medical University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 2 | Status: NOT_YET_RECRUITING